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METHODS: Patient relevant endpoints of treatment (remission of depression, 
response to treatment, no relapse, serious adverse events, adverse events, social func-
tion, anxiety, pain, cognitive function) were prioritized using pairwise comparisons of 
these outcomes. In two separate groups, twelve patients and seven experts judged on 
a 9 point scale the relative importance of pairs of two outcome measures. The geo-
metric mean of these judgments was used to derive weighting factors for the outcome 
measures (scale 0–1). RESULTS: Of all outcome measures, patients rated response to 
treatment highest (0.32), while experts rated remission of depression highest (0.48). 
Adverse events were all rated lowest by patients as well as by experts, and disease-
speciﬁ c quality of life domains such as social function (0.11 & 0.09), anxiety (0.12 
& 0.05) and cognitive function (0.13 & 0.06) were rated in between. CONCLU-
SIONS: The most important outcome measures according to the patients are, in order 
of decreasing importance: response, cognitive function, no anxiety, social function, no 
relapse, no adverse events, and remission. The AHP appears to be suitable in gaining 
an overview of the importance of patient relevant outcome measures. An additional 
advantage of AHP is that the group discussions offer insight in the question why the 
endpoints are important.
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OBJECTIVES: Outcomes research in patients with schizophrenia should take into 
account the subjective interpretation of the mood and physical changes accompanying 
medication. Those changes inﬂ uence the behavioural response to treatment and ulti-
mately the patient’s clinical outcome as mediated by his treatment compliance. Our 
aim was to assess the relationship between a speciﬁ c well-being measure, the SWN-K20 
that presents a general and 5 speciﬁ c measurement subdomains (mental functioning, 
social integration, emotional regulation, physical functioning, and self-control), and 
the 8 domains of the SF-36 v1 as a general quality of life measure. METHODS: The 
validation sample for this study comprised 97 patients diagnosed with schizophrenia 
and who were rated as clinically stable at the moment of the study (1 week test-retest 
intraclass correlation coefﬁ cient for clinical symptoms = 0.96). The patients were 
recruited as part of a multicenter psychometric trial to validate the SWN-K20 in 
Spanish. The associations between the domains of the SWN-K20 and the SF-36 were 
evaluated by the Spearman’s rank correlation test. RESULTS: All correlations among 
domains were positive and most were statistically signiﬁ cant (p < 0.05). As expected 
the bodily pain domain of the SF-36 presented the lower correlations with the 
SWN-K20 (rho range of 0.10 to 0.25), whereas the other 7 domains correlated sig-
niﬁ cantly with the total SWN-K20 score (rho range 0.49 to 0.60, all p < 0.001). 
Overall the largest correlations were obtained between the SWN-K20 and the SF-36 
domains of general health (rho = 0.53), mental health (rho = 0.60), and vitality (rho 
= 0.54). CONCLUSIONS: The positive but nevertheless moderate correlations 
observed between a speciﬁ c well-being scale, as the SWN-K20, and a general quality 
of life scale, as the SF-36, supports the inclusion of speciﬁ c and diagnose-tailored 
instruments for outcome assessments of patients with schizophrenia.
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REAL-TIME DATA COLLECTION
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OBJECTIVES: Understand features of an electronic device that allow a marked 
improvement in the quality of collected data; the importance of improved data quality 
leading to enhanced patient safety and drug labeling; populations best suited for paired 
PRO and cognitive measurement technologies; important practical considerations for 
implementation in clinical trials including training and compliance; the potential for 
using real-time parallel data for adverse event safety monitoring. METHODS: This 
session discusses using ePRO and biometric technology for parallel data capture 
emphasizing advantages, disadvantages, execution, and ways to leverage these data. 
The session will review PRO and cognitive testing technologies, including comparisons 
of devices that combine physiological measures with a patient interface with systems 
that use separate PRO input and biometric devices. RESULTS: Assessing a treatment’s 
ability to enhance or prohibit reduction of cognitive processing efﬁ ciency is an emerg-
ing study in the pharmaceutical industry. Case studies examine how the use of cogni-
tive function tests in combination with ePRO can enhance the data collection so drug 
effects otherwise unidentiﬁ ed can be determined. The speaker will discuss the future 
of ePRO combined with biometric measurements as a standard of clinical research. 
CONCLUSIONS: Clinical trial endpoints can involve collection of physiologic and 
patient-reported outcome data; a combination of subjective and objective data. Elec-
tronic forms of information capture assure trial efﬁ ciencies including edit checks and 
shorter time to database lock. ePRO provides time-stamped, legible and complete data 
from subjects. Biometric devices capture the physiological measurements. Typically, 
cognition data have been collected from patients separately from PRO data during 
clinical trials, increasing respondent burden and risk of error such as transposing 
manually entering data. The use of ePRO and biometric devices, evolution of data 
transmission technology, and greater technologic sophistication of consumers, provide 
an opportunity for parallel electronic data capture, simultaneously capturing and 
transmitting physiologic and PRO parameters in clinical studies.
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OBJECTIVES: Our intention was to investigate the prevalence of Eating Disorder and 
Body Dysmorphic Disorder in patients diaghnosed with depression, anxietay and 
borderline personality disorder by gender, using controll groups. METHODS: The 
reserach was 2009 at the Department of Phsyciatry of Szigetvár Hospital (Hungary). 
Eating Disorder Inventory was used. a self-made questionnaire aimed the body mass, 
body height and several demographic data. Inclusion criteria: ones between 18 and 
50 years age, and according to BNO F32-F34 (depression), F41 (anxiety), F6030 
(borderline personality disorder) diagnoses. Control group: participants with age 
between 18 and 50 years like that, who do not stand under a psychiatric treatment. 
The statistical analysis consisted of two sample T test, χ2-probe. RESULTS: The target 
group’s number was 82, the control group 85. In the “The feeling of the insufﬁ ciency” 
(P < 0.001), “Interpersonal distrust” (P < 0.005), “Interoceptive consciousness” (P < 
0.001) scales, the members of the control group from all three psychiatric patient 
groups reached a signiﬁ cantly lower score away. In the “Bulimia” scale there was a 
signiﬁ cantly lower score in the control group as well than the borderline in a group 
(P < 0.005), and here I found a signiﬁ cant difference between the members of two 
psychiatric groups: the anxious group reached a lower score, compared with the 
borderline group (P < 0.001). CONCLUSIONS: The three psychiatric patient groups 
did not attain the threshold value onto one of the eating disturbances relevant scales 
neither There is not a direct, causal contact between the examined psychiatric clinical 
pictures. The men’s higher result achieved on the „Bulimia” scale relates rather onto 
the binge eating disorder.
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MODELING PROGRESSION IN DEMENTIA: ASSESSING THE 
PERFORMANCE OF FIVE CLINICAL MEASURES IN SPANISH SUBJECTS 
AND CAREGIVERS
Darba J1, Kaskens L2, Lacey L3, McLaughlin T4
1Universitat de Barcelona, Barcelona, Spain; 2BCN Health, Barcelona, Spain; 3JANSSEN 
Alzheimer Immunotherapy, Dublin, Ireland; 4Alzheimer Immunotherapy Research & 
Development, Dublin, Dublin, Ireland
OBJECTIVES: The primary objective of this analysis was to compare ﬁ ve different 
clinical measures and their impact on economic modelling. Clinical measures com-
pared are the Mini-Mental State Examination (MMSE), the Cognitive Component 
Score (CCS), the Functional Component Score (FCS) the Behaviour Component Score 
(BCS), and the Dependence Scale (DS). METHODS: The MMSE, CCS, FCS, BCS and 
DS were compared in their ability to explain variation in clinical outcomes, economic- 
and other utilized resources, caregiver burden (Zarit Scale) and caregiver QoL 
(EQ-5D) using univariate (Pearson correlations) and multivariate (linear regression) 
analyses. Data on subjects and caregivers was obtained from multiple centres in Spain. 
RESULTS: In total 394 subjects, males and females aged 50 to 93 years old with mild 
cognitive impairment to severe dementia were included in this study. CCS, FCS, BCS 
and DS were moderately correlated with MMSE, with Pearson correlations ranging 
from −0.26 for BCS to −0.56 for CCS. These four clinical measures were also mod-
erately correlated with medical costs, Zarit Scale and EQ-5D while MMSE was not. 
These measures also performed better in explaining variation in medical costs, Zarit 
Scale and caregivers’ EQ-5D. MMSE performed better explaining variation in the 
number of concomitant conditions and caregiver time (hours per day). CONCLU-
SIONS: The CCS, FCS, BCS and DS are better predictors in modelling AD progression 
on a higher number of variables including medical costs, caregivers’ burden and 
caregivers QoL than the MMSE.
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OBJECTIVES: Aripiprazole has been claimed to have a beneﬁ cial effect on cognition 
with an emphasis on verbal functioning in schizophrenic patients. a prospective, 
multicenter, open-label study of Aripiprazole was set to evaluate the effect on quality 
of life, in relation to illness severity and cognitive functioning of a treatment with 
aripiprazole in schizophrenic patients. METHODS: A total of 363 schizophrenic 
patients from 18 to 65 years, treated with different typical and atypical antipsychotics 
or had no previous treatment, were switched to aripiprazole after a 2 week washout 
period. Quality of life was assessed by use of the Quality of Life Enjoyment and 
Satisfaction Questionnaire (QLESQ) at 3 separate test moments in a 12 weeks period. 
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At the same time, verbal cognitive function was assessed with the California Verbal 
Learning Test (CVLT) and the Verbal Fluency test (VF). The Clinical Global Impres-
sion-Severity (CGI-S) was assessed as well at the same visits. Statistical analysis was 
done using SAS 9.2 with the PROC MIXED module for mixed effects repeated mea-
sures analysis. RESULTS: A mixed models analyses on the QLESQ scores showed 
signiﬁ cant effects for CGI-S in all subscores but “ school “ (p = 0,1485) and for the 
verbal cognitive measures only in subscores “leisure “ for CVLT-LTFR (p = 0,0002). 
CONCLUSIONS: The observed difference over time in QLESQ values is dependent 
on the CGI-S score which contributes mostly to the prediction of the QLESQ outcome. 
Verbal cognitive outcome was not predictive . These ﬁ ndings are not in agreement 
with other publications reporting an independent contribution of both measures on 
quality of life. As the study was open-label, interpretation of the results should be 
approached with some caution.
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OBJECTIVES: The QUALITY study evaluated Quality-of-Life in schizophrenic 
patients treated with atypical antipsychotics (AAPs) in the ambulatory setting. 
METHODS: Patients (18–65 years-old) diagnosed with schizophrenia and had started 
treatment with one AAP before visit-1 (minimum: 4-weeks, maximum: 8-weeks) were 
enrolled into this Belgian study. At visit-1 patients’ demographics and medical history 
were recorded with follow-up visits after 3-, 6- and 9-months. At each visit, patients 
completed the Subjective Well-being under Neuropletic treatment short form (SWN-
K), while investigators assessed the Positive and Negative Symptom Scale (PANSS-8) 
and the Global Assessment of Functioning (GAF). RESULTS: A total of 121 patients 
(mean age 36.7 ± 10.8, 75.2% male) were enrolled with the main AAP treatments 
risperidone (31.4%), apripirazole (23.1%), quetiapine (20.7%). At baseline, the asso-
ciations between the SWN-K subscales and age, gender, positive/negative PANSS-
scores, Schizophrenia-subtype or treatment-subgroups were small. Mental-functioning 
and physical-functioning subscales were signiﬁ cantly correlated with negative PANSS-
scores, as was the emotional-regulation subscale with gender. The majority of changes 
from baseline in the SWN-K subscale scores were between −0.5 and +0.5 (range: −1.8 
to 1.6). Most mean changes were positive, suggesting that patients felt better compared 
to baseline. PANSS-8-score changes were slightly negative, suggesting decreases in 
symptom severity. 57.5% of patients showed symptom remission (PANSS-8-score ≤ 
3 after 6 months-of-treatment).GAF scores increased (study end: 8.2 ± 16.0) indicating 
improvement in the patient’s global functioning. By the study end, the number of 
hospitalizations and addictive substance use had decreased. Patients with more severe 
negative symptoms considered their mental- and physical-functioning better and men 
were more satisﬁ ed than women with their emotional-regulation. Few patients had 
sufﬁ cient disease insight; most patients had a vague notion or did not see that they 
were ill. CONCLUSIONS: The patients’ well-being seemed to improve slightly during 
the study without differences between the treatments. Patients having more severe 
negative symptoms considered their mental and physical functioning better at the 
study end.
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PRODUCTIVITY LOSS AMONG PATIENTS WITH MOOD DISORDERS
Bouwmans C1, Rutten F1, François C2, Danchenko N2, Hakkaart-van Roijen L1
1Erasmus University Rotterdam, Rotterdam, The Netherlands; 2Lundbeck SAS, Issy-les-
Moulineaux, France
OBJECTIVES: Mood disorders are generally associated with a high level of productiv-
ity loss and a substantial economic burden. The aim of this study was to measure the 
impact of mood disorders on productivity in terms of absence from work, at-work 
productivity loss, and job performance among patients in the The Netherlands. 
METHODS: Patients meeting DSM-IV criteria for depressive disorder, dysthymic 
disorder, panic disorder (with or without agoraphobia), social phobia and generalised 
anxiety disorder were included from a large naturalistic trial in 7 Dutch mental health 
care centres. The short form of the Health and Labour Questionnaire (SF-HLQ) was 
used to assess absenteeism (days absent from work), presenteeism (at-work productiv-
ity loss) and job performance (on a 3-point scale ranging from ‘not impeded’ to ‘very 
much impeded’). ANOVA analyses and t-tests were performed to explore differences 
between socio-demographic groups. RESULTS: Of the total 702 patients, two thirds 
were in paid employment. Over 3 months, 55% reported long-term absenteeism (>2 
weeks), with a mean of 73 work days lost per patient, and 13% patients reported a 
shorter-term absenteeism (<2 weeks), with a mean of 33 work days lost per patient. 
Women were absent from work for a longer (99 days) than men (46 days) (P < 0.005). 
Presenteeism accounted for a 12% productivity loss in terms of working time lost. 
The number of days at work while impeded by health problems was numerically 
higher in men than in women (7.4 vs. 5.6, p > 0.05). Overall, 31% of the patients 
had difﬁ culties in job performance when at work. CONCLUSIONS: Mood disorders 
are associated with impairment of patients’ productivity in terms of absence from 
work, presenteeism and difﬁ culties in job performance The study demonstrated a 
tendency towards lower absenteeism and higher presenteeism in men compared to 
women. 
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OBJECTIVES: The objective of this study is to analyze antidepressants and anxiolytics 
drugs usage (ATC subgroups: N06A and N05B) in two mid European, neighbouring 
countries, Croatia and Slovenia, for the 9-year period, from 2000 to 2008. Further, 
the aim was to identify the generic drugs usage in each country, the price for DDD 
for original and generic drugs, and to identify the most prescribed drugs in each drug 
group. METHODS: The data have been obtained from the International Medical 
Statistics database for Croatia and Slovenia. Drugs usage is presented in deﬁ ned daily 
doses per 1000 inhabitants per day (DDD/1000) according to the WHO Methodology. 
Financial expenditure data are presented in Euros. An average cost per DDD was 
calculated for each drug group. RESULTS: In 2008, the total usage of antidepressants 
was higher in Slovenia (42.7 DDD/1000 inhabitants/day) than in Croatia (22 
DDD/1000 inhabitants/day), and it increased in both countries during the investigated 
period. The total usage of anxiolytics is more than 3 times higher in Croatia (67.4 
DDD/1000 inhabitants/day) than in Slovenia (22.2 DDD/1000/inhabitants/day). The 
total usage of anxiolytics decreased in Slovenia in 2008 in comparison with prescrip-
tions in 2000, while it increased in Croatia for 44.3% during the same period. The 
rate of generic prescriptions among antidepressants during the investigated period was 
higher in Croatia, i.e. in Croatia 73.6% of all prescribed antidepressants were generics 
in 2008, while in Slovenia 33.5%. CONCLUSIONS: Drugs prescription patterns are 
different comparing Croatia and Slovenia. a possible reason for relatively higher usage 
of anxiolytics and lower usage of antidepressants in Croatia could be depression 
treatment with anxiolytics. This indicates the need for a more thorough analysis and 
the introduction of national drugs guidelines for rational prescribing, monitoring and 
evaluation especially anxiolytics. Although the generic drugs usage in the mentioned 
groups is relatively high, it should be further supported and promoted.
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OBJECTIVES: Antipsychotic medicines are commonly prescribed to elderly patients. 
These patients are at an increased risk of adverse drug events because of age-related 
pharmacodynamic and pharmacokinetic changes. The primary aim of the study was 
to determine antipsychotic prescribing patterns and cost to patients aged 60 years and 
older in a private health care sector primary care patient population in 2008 and 2009. 
METHODS: A retrospective, exposure-cohort drug utilization study was conducted 
on prescription data of a pharmacy group in South Africa for 2008 and 2009. No 
diagnoses were available. All records for antipsychotics (MIMS category 1.5) for 
patients 60 years and older were extracted for analysis. RESULTS: A total of 1 800 
patients in 2008 and 3 086 patients in 2009 received 7 877 and 14 538 antipsychotic 
products at a sales value of R2 785 896 and R4 928 127, respectively. The average cost 
per antipsychotic product was R353.67 in 2008 and R338.98 in 2009. Most patients 
were female (61.78% in 2008 and 57.87% in 2009). Tablets were the preferred dosage 
form. Risperidone (37.55% in 2008, and 38.20% in 2009), quetiapine (27.56% and 
28.88%) and olanzapine (10.91% and 10.24%) together accounted for more than 
75% of antipsychotics prescribed to the elderly. a high percentage of atypical antipsy-
chotics (84.23% in 2008 and 85.14% in 2009) were prescribed. Differences were 
observed between 2008 and 2009 with respect to the prescribing frequency of the 
atypical antipsychotics (chi2 = 32.624; d.f. = 6; p < 0.0001). CONCLUSIONS: Pre-
scribing patterns were relatively similar in both years. The dosages and duration of 
treatment of antipsychotics should be investigated in relation to the diagnoses for 
which they are prescribed. It is recommended that diagnoses be included in databases 
and also that qualitative studies be conducted to determine possible side effects expe-
rienced by patients.
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HEALTH CARE ORGANIZATIONS/SERVICES CLUSTERING: EXAMPLE OF 
PCTS IN ENGLAND
Millier A1, Toumi M2, Lamure M3, Aballea S1, Flostrand S1, Hansen K4
1Creativ Ceutical, Paris, France; 2University Claude Bernard Lyon 1, Lyon, Rhone Alpes, 
France; 3University Claude Berard Lyon 1, Villeurbanne, Rhone Alpes, France; 4Lundbeck 
SAS, Issy-les-Moulineaux cedex, France
OBJECTIVES: England has 152 Primary Care Trust (PCT) each having its own 
characteristics, and prescription patterns. As a consequence, PCT formulary lists 
differ, creating an additional hurdle for patient access to innovative medicines, often 
referred to as the post-code lottery. The objective of this study was to segment these 
PCTs in groups with homogeneous attitudes towards patient access for innovative 
drugs in Mental Health (MH) using a clustering analysis. METHODS: We collected 
all available information about the PCTs through public sources and the OneKey + 
database. We identiﬁ ed 62 variables per PCT and classiﬁ ed them in 5 groups: proﬁ le 
